Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Brii Bio In-licenses China Rights to Three Novel Qpex Anti-Infectives

publication date: Oct 22, 2019

Brii Biosciences, a US-China biopharma, acquired China rights to three novel anti-infectives that were discovered by Qpex Biopharma of San Diego. Qpex believes the products could become best-in-class therapeutics for multi-drug resistant gram-negative infections. Brii is an in-licensing firm dedicated to bringing novel infection treatments to China. Founded in 2018, Brii raised $260 million in its first funding. Since then, it has announced several deals including a microbiome treatment for inflammatory bowel disease. Brii is headquartered in Durham, North Caroline with China operations in Shanghai. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital